NCT03711448View on ClinicalTrials.gov

Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

September 11, 2024

Study Completion Date

September 11, 2024

Conditions
Patients Relapsing Refractory Giant Cell Arteritis
Interventions
DRUG

prednisone treatment

tapering prednisone regimen

DRUG

prednisone and ustekinumab treatment

Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)

OTHER

questionnaires

HAQ ; SF-36 ; FACIT-fatigue

BIOLOGICAL

Blood samples

Additional blood samples for immunomonitoring

Trial Locations (1)

21000

Chu Dijon Bourogne, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT03711448 - Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis | Biotech Hunter | Biotech Hunter